Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL
The Positive Opinion is based on data from the Phase 3 E1912 study, designed and conducted in the United States (U.S.) by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN)